KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Deferred Taxes (2021 - 2025)

Pacific Biosciences Of California (PACB) has 4 years of Deferred Taxes data on record, last reported at -$546000.0 in Q1 2025.

  • For Q1 2025, Deferred Taxes changed N/A year-over-year to -$546000.0; the TTM value through Dec 2025 reached -$546000.0, down 166.34%, while the annual FY2025 figure was -$546000.0, 166.34% down from the prior year.
  • Deferred Taxes reached -$546000.0 in Q1 2025 per PACB's latest filing, down from -$205000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $1.2 million in Q4 2021 and bottomed at -$718000.0 in Q4 2023.
  • Average Deferred Taxes over 4 years is -$73500.0, with a median of -$375500.0 recorded in 2024.
  • The widest YoY moves for Deferred Taxes: up 71.45% in 2024, down 71.45% in 2024.
  • A 4-year view of Deferred Taxes shows it stood at $1.2 million in 2021, then plummeted by 161.11% to -$718000.0 in 2023, then surged by 71.45% to -$205000.0 in 2024, then plummeted by 166.34% to -$546000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were -$546000.0 in Q1 2025, -$205000.0 in Q4 2024, and -$718000.0 in Q4 2023.